Cipla Ltd Stock Price Today (NSE: CIPLA)
Fundamental Score
Cipla Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Cipla Ltd share price today is ₹1409.80, down 1.15% on NSE/BSE as of 25 May 2026. Cipla Ltd (CIPLA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.23L (Cr). The 52-week high for CIPLA share price is ₹N/A and the 52-week low is ₹1170.00. At a P/E ratio of 22.62x, CIPLA is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 17.77% and a debt-to-equity ratio of 0.01.
Cipla Ltd Share Price Chart — NSE/BSE Historical Performance
Cipla Ltd share price chart: 14.66% return over the past month. 52-week high ₹N/A, 52-week low ₹1170.00.
Cipla Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1420.00 | ₹1426.60 | ₹1408.70 | ₹1409.80 | 13.79L (Cr) | |
| ₹1422.00 | ₹1442.10 | ₹1411.80 | ₹1426.20 | 20.14L (Cr) | |
| ₹1436.70 | ₹1444.50 | ₹1425.20 | ₹1432.10 | 11.39L (Cr) | |
| ₹1362.20 | ₹1442.00 | ₹1362.20 | ₹1436.70 | 91.67L (Cr) | |
| ₹1279.10 | ₹1356.60 | ₹1274.70 | ₹1327.60 | 60.14L (Cr) | |
| ₹1304.60 | ₹1309.00 | ₹1289.00 | ₹1292.30 | 13.98L (Cr) | |
| ₹1347.00 | ₹1350.00 | ₹1300.10 | ₹1304.90 | 14.28L (Cr) | |
| ₹1355.00 | ₹1366.70 | ₹1341.30 | ₹1347.00 | 10.45L (Cr) | |
| ₹1370.00 | ₹1379.50 | ₹1360.10 | ₹1362.30 | 12.48L (Cr) | |
| ₹1340.00 | ₹1372.00 | ₹1333.10 | ₹1364.40 | 18.55L (Cr) |
Cipla Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1320.00 | ₹1444.50 | ₹1274.70 | ₹1409.80 | +6.80% | |
| ₹1255.00 | ₹0.00 | ₹0.00 | ₹1309.60 | +4.35% | |
| ₹1313.00 | ₹1354.50 | ₹1215.00 | ₹1224.20 | -6.76% | |
| ₹1330.00 | ₹1381.30 | ₹1293.10 | ₹1348.20 | +1.37% | |
| ₹1512.00 | ₹1539.70 | ₹1281.70 | ₹1324.00 | -12.43% | |
| ₹1532.00 | ₹1536.30 | ₹1475.90 | ₹1511.30 | -1.35% | |
| ₹1502.90 | ₹1538.40 | ₹1490.30 | ₹1531.30 | +1.89% | |
| ₹1505.00 | ₹1673.00 | ₹1490.80 | ₹1501.30 | -0.25% | |
| ₹1589.40 | ₹1599.00 | ₹1475.20 | ₹1503.30 | -5.42% | |
| ₹1544.00 | ₹1607.80 | ₹1464.10 | ₹1589.40 | +2.94% | |
| ₹1505.90 | ₹1579.90 | ₹1454.50 | ₹1554.60 | +3.23% | |
| ₹1468.00 | ₹1541.00 | ₹1458.00 | ₹1505.90 | +2.58% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Cipla is a complex generics play with India as a safety net; USFDA setbacks or domestic margin compression will crush the stock.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Cipla received USFDA approval for Nintedanib Capsules for Idiopathic Pulmonary Fibrosis. The company is set for immediate launch, targeting a $3.76 billion market. Also, Cipla allotted 1,954 equity shares under employee stock option schemes.
CORE STORY (THE REAL GAME)
Cipla is transitioning from generics to complex generics and specialty products, particularly in the US market, while maintaining dominance in the Indian respiratory market. The key is navigating US pricing pressures and regulatory hurdles while leveraging its India business for stability.
- USFDA approval for Nintedanib Capsules
- Strong position in the Indian respiratory market
- Growth in chronic therapies
- Successful US generics launches
- Strong Q4 FY26 earnings
- Resolution of US tariff uncertainty
- Promoter holding below 40%
- US tariff risks
- Pricing pressure in US generics market
FII decreased holdings by 0.7%, DII increased holdings by 1.0%.
Indian pharma industry projected to reach $130 billion by 2030, driven by global demand and innovation.
Yes. Free Cash Flow 5Y: ₹14019.84 Cr.
Cipla needs to execute on US launches and maintain India momentum. Watch for Q4 FY26 results and US regulatory updates.
Primary Thesis Risk
Failure to execute on US complex generics pipeline.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Cipla Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Cipla Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CIPLA across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (17.77%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (22.72%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (23.29%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 22.62 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Excellent EPS Growth (28.64% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (28.68% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (127.03x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹14019.84 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 54.52%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Low Promoter Commitment (29.21%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Cipla Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Cipla Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Cipla LtdCipla Ltd...Selected✓ CIPLA • 500087 | 59/100 | ₹1409.80₹1410 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6912.00₹6912 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1512.80₹1513 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5470.00₹5470 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Abbott India LtdAbbott India Lt... ABBOTINDIA • 500488 | 65/100 | ₹27795.00₹27795 | ₹63358.16₹63358.16 | 41.99Average 42.0 Average | 35.68%Excellent 35.68% Excellent | 46.25%Excellent 46.25% Excellent | 0.05Excellent 0.1 Excellent | 18.98%Excellent 18.98% Excellent | 9.38%Good 9.38% Good | 1.59% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
- Lupin Ltd share price95148.15 Cr
Cipla Ltd PE Ratio History
Historical price-to-earnings ratio for CIPLA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹65.24 | ₹1511.30 | 23.2x |
| FY 2024 | ₹51.01 | ₹1529.00 | 30x |
| FY 2023 | ₹34.69 | ₹1246.30 | 35.9x |
| FY 2022 | ₹31.17 | ₹1075.95 | 34.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Cipla Ltd Dividend History
Annual cash dividends paid by CIPLA — dividend yield 0.85%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1049.83 Cr |
| FY 2024 | ₹686.17 Cr |
| FY 2023 | ₹403.50 Cr |
| FY 2022 | ₹403.35 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Cipla Ltd Quarterly Performance
Latest quarterly metrics for CIPLA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
7.64%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
3.73%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.97%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
28.68%
Compounded annual net profit growth over 5 years
Cipla Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CIPLA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Cipla Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Cipla Ltd (CIPLA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Cipla Ltd
About CIPLA (Cipla Ltd)
Cipla Ltd is a global pharmaceutical powerhouse, recognized for its commitment to providing affordable and accessible healthcare solutions. From its state-of-the-art manufacturing ...facilities, Cipla formulates and distributes a wide range of medications, catering to diverse medical needs across the globe. The company distinguishes itself through its dedication to innovation, constantly pushing the boundaries of pharmaceutical research and development to create novel treatments and improve existing therapies. With a strong emphasis on quality and patient well-being, Cipla has established itself as a trusted partner for healthcare professionals and patients alike, ensuring that life-saving medications reach those who need them most. Cipla's operations are strategically structured, encompassing the development, production, and marketing of a comprehensive portfolio of pharmaceutical products. Their offerings range from complex generics to innovative formulations, all adhering to the highest international quality standards. The company's diverse therapeutic focus covers critical areas such as respiratory diseases, oncology, HIV/AIDS, and cardiovascular health, demonstrating its commitment to addressing some of the world's most pressing health challenges. Through strategic partnerships and a robust distribution network, Cipla ensures that its products are readily available in both developed and emerging markets, contributing to improved health outcomes on a global scale. Driven by a mission to make a difference in people's lives, Cipla continually invests in cutting-edge technologies and sustainable manufacturing practices. The company's commitment to corporate social responsibility is evident in its various initiatives aimed at promoting healthcare access, supporting community development, and protecting the environment. By fostering a culture of innovation, collaboration, and ethical conduct, Cipla attracts and retains top talent, enabling it to maintain its competitive edge in the dynamic pharmaceutical industry. Through its unwavering dedication to quality, affordability, and social impact, Cipla continues to shape the future of healthcare and improve the lives of millions worldwide.
Company Details
Key Leadership
Corporate Events
CIPLA Share Price: Frequently Asked Questions
What is the current share price of Cipla Ltd?
Cipla Ltd (CIPLA) trades at ₹1409.80 on NSE and BSE. Market cap ₹1.23L (Cr). Educational data only.
What is the P/E ratio of Cipla Ltd?
Cipla Ltd has a P/E of 22.62x vs industry average 31.77x.
What is the Bull Run score for Cipla Ltd?
Cipla Ltd has a Bull Run score of 59/100 based on 25+ financial parameters.
Does Cipla Ltd pay dividends?
Cipla Ltd has a dividend yield of 0.85%. Past dividends don't guarantee future payments.
What is the ROE of Cipla Ltd?
Cipla Ltd has ROE of 17.77%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Cipla Ltd?
Cipla Ltd has debt-to-equity of 0.01.
Is Cipla Ltd a good investment?
Bull Run gives Cipla Ltd a score of 59/100. This is not investment advice — consult a SEBI-registered advisor.